Table 2. Univariate Cox-hazard analysis for cardiovascular events.
| Hazard ratio | 95% CI | P value | |
|---|---|---|---|
| Male gender (0 = female; 1 = male) | 1.42 | 0.91–2.23 | 0.122 |
| Age (1 year) | 1.04 | 1.02–1.06 | < 0.001 |
| Dialysis duration (1 month) | 1.00 | 1.00–1.01 | 0.002 |
| Diabetes mellitus (0 = no; 1 = yes) | 1.21 | 0.76–1.93 | 0.424 |
| Body mass index (1 kg/m2) | 0.98 | 0.93–1.04 | 0.554 |
| Smoking habit (0 = no; 1 = yes) | 1.02 | 0.63–1.64 | 0.941 |
| Alcohol consumption (0 = no; 1 = yes) | 0.78 | 0.50–1.23 | 0.288 |
| Systolic blood pressure before dialysis (1 mmHg) | 0.99 | 0.97–1.00 | 0.055 |
| Diastolic blood pressure before dialysis (1 mmHg) | 0.96 | 0.95–0.98 | < 0.001 |
| Cardiothoracic ratio (1%) | 1.05 | 1.00–1.11 | 0.040 |
| Left ventricular ejection fraction (1%) | 0.98 | 0.96–1.00 | 0.010 |
| Left ventricular mass index (1 g/m2) | 1.00 | 0.99–1.00 | 0.342 |
| Serum aspartate aminotransferase (1 IU/L) | 0.94 | 0.86–1.03 | 0.172 |
| Serum alanine aminotransferase (1 IU/L) | 0.97 | 0.90–1.05 | 0.433 |
| Serum γ-glutamyl transferase (1 IU/L) | 1.01 | 0.93–1.10 | 0.859 |
| Blood hemoglobin (1 g/dL) | 1.13 | 0.84–1.36 | 0.191 |
| Serum albumin (1 g/dL) | 0.37 | 0.21–0.64 | < 0.001 |
| Serum calcium (1 mg/dL) | 1.18 | 0.90–1.54 | 0.233 |
| Serum inorganic phosphorus (1 mg/dL) | 1.04 | 0.85–1.26 | 0.714 |
| Serum intact parathyroid hormone (1 pg/mL) | 1.00 | 1.00–1.00 | 0.849 |
| Serum C-reactive protein (1 mg/L) | 1.08 | 0.99–1.18 | 0.097 |
| Serum hemoglobin A1c (1%) | 1.15 | 0.83–1.64 | 0.425 |
| Serum total cholesterol (1 mg/dL) | 1.00 | 0.99–1.00 | 0.099 |
| Serum high-density lipoprotein cholesterol (1 mg/dL) | 0.99 | 0.96–1.03 | 0.700 |
| Serum triglyceride (1 mg/dL) | 1.00 | 1.00–1.00 | 0.783 |
| Serum β2 microglobulin (1 ng/mL) | 0.99 | 0.94–1.03 | 0.560 |
| Plasma B-type natriuretic peptide (1 pg/mL) | 1.00 | 1.00–1.00 | 0.667 |
| Plasma aldosterone (1 pg/mL) | 1.00 | 1.00–1.00 | 0.138 |
| Serum PIIINP (1 U/mL) | 1.53 | 1.40–1.68 | < 0.001 |
| Medications | |||
| α1 blockers (0 = no; 1 = yes) | 0.52 | 0.23–1.19 | 0.123 |
| β blockers (0 = no; 1 = yes) | 0.99 | 0.57–1.72 | 0.984 |
| Calcium channel blockers (0 = no; 1 = yes) | 0.81 | 0.47–1.38 | 0.437 |
| ACE inhibitors (0 = no; 1 = yes) | 0.74 | 0.34–1.61 | 0.446 |
| ARB (0 = no; 1 = yes) | 0.99 | 0.57–1.71 | 0.965 |
| Nitrates (0 = no; 1 = yes) | 1.22 | 0.45–3.33 | 0.701 |
| Antiplatelet drugs (0 = no; 1 = yes) | 0.60 | 0.34–1.06 | 0.079 |
| Anticoagulation drugs (0 = no; 1 = yes) | 0.70 | 0.10–5.02 | 0.721 |
| Statins (0 = no; 1 = yes) | 0.82 | 0.30–2.25 | 0.704 |
| Vitamin D (0 = no; 1 = yes) | 1.17 | 0.75–1.84 | 0.485 |
PIIINP, aminoterminal propeptide of type III procollagen; ACE, angiotensin I converting enzyme; ARB, angiotensin II type-1 receptor blocker.